NYSE$TDOC

Teladoc Health Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Teladoc Health reported its financial results for the fourth quarter and full year ended December 31, 2024.

Teladoc Health concluded 2024 with a solid performance in Q4, despite a slight revenue decrease. Integrated Care showed growth and margin expansion, while BetterHelp faced challenges in a difficult operating environment. The company is focused on execution and cost structure improvements for 2025.

  • Fourth Quarter 2024 revenue decreased 3% year-over-year to $640.5 million.
  • Net loss for Fourth Quarter 2024 was $48.4 million, or $0.28 per share.
  • Adjusted EBITDA for Fourth Quarter 2024 decreased 35% year-over-year to $74.8 million.
  • Integrated Care segment revenue increased 2%, while BetterHelp segment revenue decreased 10% in Q4 2024.

Headline financials

Total Revenue

$640M

Previous: $661M-3.0%
EPS (adj)

-$0.28

Previous: -$0.17-64.7%
Adjusted EBITDA

$74.8M

No prior period
Operating Cash Flow

$85.9M

No prior period
Capex

$29.6M

No prior period
Total Visits

4.4M

No prior period
U.S. Integrated Care Members

93.8M

No prior period
BetterHelp Paying Users

400.0K

No prior period
Net Income

-$48.4M

Previous: -$28.9M-67.6%
Operating Income

-$48.2M

Previous: -$35.1M-37.4%
Gross Profit

$421M

Previous: $370M+13.8%

Revenue & EPS history

Teladoc · Revenue · Quarterly

$640M

Q4 2024-3%vs Q4 2023
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Teladoc · $660M total across 2 segments · Q3 2023

  • Integrated Care
    $374M
  • BetterHelp
    $286M

Forward guidance

For the full year 2025, Teladoc Health expects revenue between $2,468 million and $2,576 million, adjusted EBITDA between $278 million and $319 million, and net loss per share between ($1.10) and ($0.50). Free cash flow is projected to be between $190 million and $220 million. For the first quarter of 2025, revenue is expected to be between $608 million and $629 million, adjusted EBITDA between $47 million and $59 million, and net loss per share between ($0.40) and ($0.15).

Tailwinds

  • Anticipated contribution from the acquisition of Catapult Health.
  • Integrated Care revenue growth percentage expected between 0.00% and 3.00% for FY 2025.
  • Integrated Care adjusted EBITDA margin expected between 14.30% and 15.30% for FY 2025.
  • U.S. Integrated Care Members projected to be between 101 million and 103 million for FY 2025.
  • Integrated Care revenue growth percentage expected between (0.50%) and 2.00% for Q1 2025.

Headwinds

  • BetterHelp revenue growth percentage expected to be negative, between (9.75%) and (3.75%) for FY 2025.
  • BetterHelp adjusted EBITDA margin expected to be lower, between 6.25% and 7.75% for FY 2025.
  • BetterHelp revenue growth percentage expected to be negative, between (13.50%) and (9.00%) for Q1 2025.
  • BetterHelp adjusted EBITDA margin expected to be lower, between 2.00% and 4.25% for Q1 2025.
  • The outlook does not include the impact of any purchase accounting or potential impairments resulting from the Catapult Health acquisition.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.2%

Avg return

Earnings day

-2.1%

Avg return

5 days after

-1.6%

Avg return

30 days after

49%

21 / 43 earnings

Positive

+23.7%

Q2 2023

Best reaction

-42.0%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.8%+11.9%+27.9%
Q4 2025+15.5%+9.7%+10.5%
Q3 2025+6.2%-3.0%-7.8%
Q1 2025-2.8%-5.7%-3.8%
Q4 2024-13.6%-16.3%-26.4%
Q3 2024+0.9%-0.6%+34.3%
Q2 2024-11.7%-21.9%-26.3%
Q1 2024-5.2%-7.1%-16.4%
Q4 2023-25.6%-31.1%-27.3%
Q3 2023-3.3%-13.5%-5.3%
Q2 2023+23.7%+20.9%-6.1%
Q1 2023+3.4%+2.2%-14.4%
Q4 2022-3.9%-5.4%-12.2%
Q3 2022+6.4%+10.8%+3.2%
Q2 2022-11.4%-8.4%-20.1%
Q1 2022-42.0%-35.7%-38.1%
Q4 2021-5.4%+8.8%+6.8%
Q3 2021+5.6%+7.2%-22.4%
Q2 2021+1.4%-0.9%-5.5%
Q1 2021-10.1%-14.1%-20.7%
Q4 2020-14.2%-12.7%-30.9%
Q3 2020-2.3%-14.6%-11.9%
Q2 2020+11.5%+11.5%-1.9%
Q1 2020-9.1%-3.8%-3.9%
Q4 2019+14.1%+5.1%+38.6%
Q3 2019+7.1%+12.3%+17.1%
Q2 2019+1.9%-6.5%-17.5%
Q1 2019-2.0%+2.9%-1.8%
Q4 2018-4.5%-6.3%-17.5%
Q3 2018+4.6%-8.6%-9.9%
Q2 2018+9.0%+10.3%+29.6%
Q1 2018+5.7%-1.9%+18.4%
Q4 2017+4.0%+8.8%+4.5%
Q3 2017-3.0%-5.4%+8.0%
Q2 2017-7.1%-2.6%+5.5%
Q1 2017+23.3%+26.9%+46.3%
Q4 2016+6.8%-4.8%+13.4%
Q3 2016+6.2%+8.6%+19.4%
Q2 2016-16.1%-9.0%+2.9%
Q1 2016-1.5%
Q4 2015-7.3%
Q3 2015-10.6%
Q2 2015+3.6%
Q1 2015
Q4 2014
Q3 2014
Q2 2014
Q1 2014

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro